Samsung In Talks To Buy Biogen For $42 Bn: Report
Shares of Biogen surged Wednesday following a report that South Korean giant Samsung Group is in talks to acquire the US biotech company for more than $40 billion. Biogen, which is known for its Alzheimer’s drug Aduhelm and a neurology-focused medication pipeline, approached Samsung on a potential deal that could be valued at more than …
Samsung In Talks To Buy Biogen For $42 Bn: Report Read More »